NCT04795128View on ClinicalTrials.gov

A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 7, 2021

Primary Completion Date

August 15, 2023

Study Completion Date

August 15, 2023

Conditions
Hematologic Malignancy
Interventions
BIOLOGICAL

IBI322

Recombinant anti-human CD47/PD-L1 bispecific antibody injection

Trial Locations (1)

Unknown

The Second Affiliated Hospital Zhejiang University School of Medicine, Zhejiang

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY